Literature DB >> 6378086

Distribution of ceftazidime in ascitic fluid.

G Benoni, E Arosio, M G Raimondi, E Apolloni, E Passarella, A Lechi, G P Velo.   

Abstract

The pharmacokinetics of ceftazidime were investigated in eight normal subjects and eight patients with ascites after intravenous administration of 1 g of the drug. Samples of blood and ascitic fluid were collected for 6 h after dosage, and urine samples were collected for 24 h. Pharmacokinetic data were calculated by using a one-compartment model. The apparent volume of distribution and half-life of elimination (t1/2 beta) in patients with ascites were approximately three times those in normal subjects. In contrast, renal clearance was greater in the normal subjects. With respect to ascites, the mean area under the concentration-time curve was 95.3 +/- 38.3 micrograms X h/ml. The mean ratio of the area under the concentration-time curve for ascitic fluid to that for plasma was 69.9% (+/- 38.2). These data show that ceftazidime rapidly diffuses into the peritoneal space, in which concentrations greater than 10 micrograms/ml were present for at least 6 h.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6378086      PMCID: PMC185636          DOI: 10.1128/AAC.25.6.760

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Pharmacokinetics of ampicillin in cirrhosis.

Authors:  G P Lewis; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Penetration of four cephalosporins into tissue fluid in man.

Authors:  A P Gillett
Journal:  Lancet       Date:  1978-05-06       Impact factor: 79.321

3.  A diffusion chamber technique for measuring concentrations of antibiotics in interstitial fluid.

Authors:  G Laber; E Schütze; R Leskova; R Kolb; A Georgopoulos
Journal:  Infection       Date:  1980       Impact factor: 3.553

4.  [Pharmacokinetics of propicillin in geriatric patients in comparison with younger adults].

Authors:  C Simon; V Malerczyk; U Müller; G Müller
Journal:  Dtsch Med Wochenschr       Date:  1972-12-29       Impact factor: 0.628

5.  The passage of cephalothin into and out of ascitic fluid.

Authors:  D E Wilson; T C Chalmers; M A Madoff
Journal:  Am J Med Sci       Date:  1967-04       Impact factor: 2.378

6.  LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity.

Authors:  G M Trager; G W White; V M Zimelis; A P Panwalker
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

7.  [Metabolism and kinetics of ampicillin elimination in cirrhosis. Therapeutical consequences (author's transl)].

Authors:  J Chalas; D Labayle; J Macarrio; D Barraud; A Lindenbaum; C Buffet; J C Chaput
Journal:  Sem Hop       Date:  1980 Mar 8-15

8.  Interstitial concentration of antibiotics and their significance for an adequate dosage.

Authors:  H U Eickenberg
Journal:  Infection       Date:  1980       Impact factor: 3.553

9.  GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity.

Authors:  C H O'Callaghan; P Acred; P B Harper; D M Ryan; S M Kirby; S M Harding
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

10.  GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae.

Authors:  L Verbist; J Verhaegen
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

View more
  6 in total

Review 1.  Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.

Authors:  Federico Pea; Pierluigi Viale; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Dosage adjustment for ceftazidime in patients with impaired renal function.

Authors:  R van Dalen; T B Vree; A M Baars; E Termond
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Multiple-dose pharmacokinetics of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure during intermittent hemofiltration.

Authors:  J M Kinowski; J E de la Coussaye; F Bressolle; D Fabre; G Saissi; O Bouvet; M Galtier; J J Eledjam
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics of newer antibacterial agents in liver disease.

Authors:  J F Westphal; J M Brogard
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 6.  Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R N Brogden
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.